- Reuters•4 hours ago
GlaxoSmithKline plans 275 million pounds ($361 million) of new investments at three drug manufacturing sites in Britain, signalling its confidence in the country despite last month's vote to leave the European Union. Britain's biggest drugmaker, which had argued against Brexit before the referendum, believes the UK remains an attractive place for making medicines, thanks to a skilled workforce and relatively low tax rates. "It is testament to our skilled UK workforce and the country's leading position in life sciences that we are making these investments in advanced manufacturing here," said Chief Executive Andrew Witty.
|Bid||4,652.00 x 6100|
|Ask||4,654.00 x 13000|
|52wk Range||3,680.00 - 4,701.50|
|Day's Range||4,640.00 - 4,698.50|
|Avg Vol (3m)||2,620,093|
As of 7:41 AM EDT. LSE Delayed Price. Market open.